Promedior, a clinical stage biotechnology company focused on fibrosis, is opening its new office and laboratory space at 101 Hartwell Avenue, Lexington, Mass.

Consolidating all of its operations, the new facility will serve as the company's headquarters and completes the corporate move from the suburbs of Philadelphia, Penn. Promedior's new facility includes state-of-the-art laboratories to support product development and commercialization of the company's novel pentraxin-2 therapeutics to treat fibrosis, including a number of rare diseases such as idiopathic pulmonary fibrosis (IPF) and myelofibrosis.

"Our new facility in Massachusetts positions us to expand our capabilities and accelerate our products forward, as we attract a highly-skilled team to develop and commercialize breakthrough therapeutics to treat fibrotic diseases for which there are few, if any, treatment options for patients," said Suzanne L. Bruhn, Ph.D., president and CEO of Promedior.

Promedior's pipeline of therapeutics for fibrosis includes drug development programs targeted at rare diseases. The company joins more than 50 biotechnology companies located in New England that have commercial drugs or drug development programs for rare diseases.

Promedior's growth plans in 2013 include advancing a clinical program in myelofibrosis and moving forward with a program in ocular disease.